Skip to main content

Table 1 Change in the number of stool specimens tested for C. difficile and the rate of positive specimens according to the laboratories between 2013 and 2014

From: Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies

Laboratory Testing algorithm Number of rejected samples Number of positive results
2013 2014 2013 2014 p 2013 2014 p
A GDH + EIAa GDH + NAATd 10/133 (7.5) 34/137 (24.8) < 0.001 9/123 (7.3) 10/103 (9.7) 0.52
B GDH + EIAb GDH + NAATd 89/776 (11.5) 83/653 (12.7) 0.47 29/687 (4.1) 46/570 (8.1) 0.003
C GDH + EIAb GDH + NAATd 0/244 (0.0) 30/314 (9.6) < 0.001 21/244 (8.6) 20/284 (7.0) 0.50
D GDH + EIAb + TC GDH + NAATd 0/225 (0.0) 0/193 (0.0) * 18/225 (8.0) 14/193 (7.3) 0.77
Total 99/1378 (7.1) 147/1297 (11.3) < 0.001 77/1279 (6.0) 90/1150 (7.8) 0.07
E EIAc GDH + EIAa 6/42 (14.2) 13/44 (29.5) 0.88 2/42 (4.7) 6/31 (19.4) 0.09
F GDH + EIAb GDH + EIAb 0/73 (0.0) 0/85 (0.0) * 6/73 (8.2) 4/85 (4.7) 0.37
G GDH + EIAb GDH + EIAb 47/178 (26.4) 25/152 (16.4) 0.82 20/147 (13.6) 17/127 (13.4) 0.96
H GDH + EIAb + TC GDH + EIAb + TC 0/228 (0.0) 0/267 (0.0) * 12/228 (5.3) 8/267 (3.0) 0.20
I GDH + EIAb + TC GDH + EIAb + TC 23/211 (10.9) 5/162 (3.1) 0.008 17/188 (9.0) 11/157 (7.0) 0.49
Total 76/648 (11.7) 43/710 (6.1) < 0.001 57/678 (8.4) 46/667 (6.9) 0.30
  1. The number of rejected samples is expressed as the number of samples rejected/total number of samples collected (percent). The number of C. difficille infection (CDI)-positive samples is expressed as the number of CDI-positive samples/total number of samples tested (percent). The number of tests per patient is expressed as the number of tested samples/number of patients (ratio). A to D, laboratories that introduced nucleic acid amplification tests (NAATs). E to I, laboratories that did not introduce NAATs
  2. GDH glutamate dehydrogenase by enzyme immunoassay, EIA toxin enzyme immunoassay, TC toxigenic culture
  3. Statistical analysis was performed using the Chi square test. A p value < 0.05 was considered significant
  4. *Not applicable
  5. Methods: aC. Diff. Quik Chek Complete©, Alere (Waltham, MA, USA); bC. Diff. Quik Chek GDH©, Alere and TOX A/B Quik Chek©, Alere; c. And TOX A/B Quik Chek©, Alere; dImmunoCard® C. difficile GDH, Meridian (Cincinnati, OH, USA) and NAAT illumigene®, Mridiane